Claims
- 1. A cancer therapeutic agent, comprising a cancer targeting molecule linked to a liver-expressed chemokine (LEC).
- 2. A cancer therapeutic agent according to claim 1, wherein said cancer targeting molecule is an antibody.
- 3. A cancer therapeutic agent according to claim 2, wherein said antibody is specific for a tumor cell-surface antigen.
- 4. A cancer therapeutic agent according to claim 2, wherein said antibody is specific for a stromal component of a tumor.
- 5. A cancer therapeutic agent according to claim 2, wherein said antibody is specific for an intracellular antigen.
- 6. A cancer therapeutic agent according to claim 5, wherein said antibody is specific for an intranuclear antigen.
- 7. A cancer therapeutic agent according to claim 6, wherein said antibody is a murine, chimeric, humanized, or human form of murine antibody TNT-1, TNT-2, TNT-3 or NHS76.
- 8. A cancer therapeutic agent according to claim 1, wherein said cancer targeting molecule and LEC are covalently linked.
- 9. A cancer therapeutic agent according to claim 1, wherein said cancer targeting molecule is a protein linked to LEC by genetic fusion.
- 10. A cancer therapeutic agent according to claim 9, wherein LEC is fused at its C-terminus to the N-terminus of said cancer targeting molecule.
- 11. A cancer therapeutic agent according to claim 10, wherein the cancer targeting molecule is an antibody and wherein LEC is fused to the N-terminus of the light or heavy chain of said antibody or wherein LEC is fused to the N-terminus of the light and the heavy chain of said antibody.
- 12. A composition, comprising the cancer therapeutic agent of claim 1 and a pharmaceutically acceptable carrier.
- 13. A method of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual, comprising administering an effective amount of a cancer therapeutic agent of claim 1 to the individual wherein said cancer therapeutic agent localizes to the cancer cells or tumor in the individual.
- 14. A method according to claim 13 further comprising reducing the activity of immunoregulatory T cells in the individual.
- 15. A method according to claim 14 wherein said reducing the activity of immunoregulatory T cells involves removing ex vivo immunoregulatory T cells from the individual.
- 16. A method according to claim 14 wherein said reducing the activity of immunoregulatory T cells involves depleting or inactivating in vivo immunoregulatory T cells in the individual.
- 17. A method according to claim 14 wherein said reducing the activity of immunoregulatory T cells is achieved using at least one antibody that binds to the immunoregulatory T cells.
- 18. A method according to claim 17 wherein said at least one antibody is specific for the IL-2 receptor.
- 19. A method according to claim 17 wherein said antibody specific for the IL-2 receptor is an antibody specific for CD25.
- 20. A method according to claim 14 wherein said reducing the activity of immunoregulatory T cells is performed before administering said cancer therapeutic agent.
- 21. A method according to claim 14 further comprising administering T cells which have cytotoxic activity against the cancer.
- 22. A method according to claim 21 wherein said administering T cells comprises removing T cells from the individual, activating the T cells, and then administering the activated T cells to the individual.
- 23. A method of reducing or inhibiting the development of metastatic cancer in an individual suffering from cancer, comprising administering an effective amount of a cancer therapeutic agent of claim 1 to the individual, wherein said cancer therapeutic agent localizes to cancer cells or tumor in the individual.
- 24. A method according to claim 23 further comprising reducing the activity of immunoregulatory T cells in the individual.
- 25. A method according to claim 24 wherein said reducing the activity of immunoregulatory T cells is achieved using at least one antibody that binds to the immunoregulatory T cells.
- 26. A method according to claim 25 wherein said at least one antibody is specific for the IL-2 receptor.
- 27. A method according to claim 26 wherein said antibody specific for the IL-2 receptor is an antibody specific for CD25.
- 28. A method according to claim 24 wherein said reducing the activity of immunoregulatory T cells is performed before administering said cancer therapeutic agent.
- 29. A method according to claim 23 further comprising administering T cells which have cytotoxic activity against the metastatic cancer cells.
- 30. A method according to claim 29 wherein said administering T cells comprises removing T cells from the individual, activating the T cells, and then administering the activated T cells to the individual.
CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
[0001] This application is a An application claiming the benefit under 35 USC 119(e) U.S. application Ser. No. 60/447,714, filed Feb. 14, 2003, incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60447714 |
Feb 2003 |
US |